Obstet Gynecol Sci.  2014 Jan;57(1):28-36.

Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer

• Shin NR
• Lee YY
• Kim SH
• Choi CH
• Kim TJ
• Lee JW
• Bae DS
• Kim BG

Abstract

OBJECTIVE
The purpose of this study is to investigate the prognostic role of pretreatment anemia in patients with early cervical cancer who underwent radical hysterectomy.
METHODS
In this study, we retrospectively enrolled patients with early cervical cancer (International Federation of Obstetrics and Gynecology stage IB to IIA) who were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007.
RESULTS
We retrospectively enrolled 805 patients. Median pretreatment hemoglobin (Hb) level was 12.8 g/dL (4.0-16.9) in all patients. Ninety-ninth out of 805 patients had pretreatment anemia (12.3%). Pretreatment anemia was significantly associated with large tumor size, advanced clinical stage, and parametrial invasion. In multivariate analysis, higher pretreatment Hb entailed better prognostic significance in disease free survival (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.078-0.99) but not in overall survival (HR, 0.94; 95% CI, 0.80-1.10).
CONCLUSION
In conclusion, we found that the negative association between pretreatment Hb level and tumor size and the impact of anemia before treatment on disease free survival adjusted for other factors including clinical stage and pathological findings in early stage cervical cancer.

Keyword

Anemia; Hemoglobins; Prognosis; Survival; Uterine cervical neoplasms

MeSH Terms

Anemia
Disease-Free Survival
Gynecology
Humans
Hysterectomy
Korea
Multivariate Analysis
Obstetrics
Prognosis
Retrospective Studies
Seoul
Uterine Cervical Neoplasms*

Figure

• 

  Fig. 1 (A) Disease free survival and (B) overall survival according to the pretreatment hemoglobin (Hb, with anemia vs. without anemia) in patients with early cervical cancer.

• 

  Fig. 2 The association between pretreatment hemoglobin (Hb) level and International Federation of Obstetrics and Gynecology (FIGO) clinical stage (A) and tumor size (B).

Reference

1. Ferlay J. International Agency for Research on Cancer. Cancer incidence, mortality, and prevalence worldwide: IARC CancerBase GLOBOCAN 2008. Lyon: IARD Press;2008.

2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277–300.

3. Berek JS. Berek & Novak's gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins;2007.

4. Kupets R, Covens A. Is the International Federation of Gynecology and Obstetrics staging system for cervical carcinoma able to predict survival in patients with cervical carcinoma?: an assessment of clinimetric properties. Cancer. 2001; 92:796–804.

5. Soisson AP, Soper JT, Clarke-Pearson DL, Berchuck A, Montana G, Creasman WT. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990; 37:390–395.

6. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999; 73:177–183.

7. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18:1606–1613.

8. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91:2214–2221.

9. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP. Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother Oncol. 2000; 57:13–19.

10. Choi YS, Yi CM, Sin JI, Ye GW, Shin IH, Lee TS. Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int J Gynecol Cancer. 2006; 16:1846–1854.

11. Obermair A, Cheuk R, Horwood K, Neudorfer M, Janda M, Giannis G, et al. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. Int J Gynecol Cancer. 2003; 13:633–639.

12. Seo Y, Yoo SY, Kim MS, Yang KM, Yoo HJ, Kim JH, et al. Nomogram prediction of overall survival after curative irradiation for uterine cervical cancer. Int J Radiat Oncol Biol Phys. 2011; 79:782–787.

13. Lee YY, Choi CH, Sung CO, Do IG, Hub SJ, Kim HJ, et al. Clinical significance of changes in peripheral lymphocyte count after surgery in early cervical cancer. Gynecol Oncol. 2012; 127:107–113.

14. Tesarova P, Kvasnicka J. Treatment of anemia in patients with tumors. Cas Lek Cesk. 1995; 134:647–650.

15. Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998; 83:726–731.

16. Wilairat W, Benjapibal M. Presence of anemia and poor prognostic factors in patients with endometrial carcinoma. Asian Pac J Cancer Prev. 2012; 13:3187–3190.

17. Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma. 1975; 22:655–660.

18. Thomson JM, Spratt JS Jr. Factors affecting survival in over 500 patients with stage II carcinoma of the cervix. Radiology. 1977; 123:181–183.

19. Kapp DS, Fischer D, Gutierrez E, Kohorn EI, Schwartz PE. Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys. 1983; 9:445–455.

20. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys. 1989; 16:37–42.

21. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999; 86:1528–1536.

22. Kapp KS, Poschauko J, Geyer E, Berghold A, Oechs AC, Petru E, et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 54:58–66.

23. Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J, Pickel H, Lahousen M, et al. Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1998; 42:531–540.

24. Barkati M, Fortin I, Mileshkin L, Bernshaw D, Carrier JF, Narayan K. Hemoglobin level in cervical cancer: a surrogate for an infiltrative phenotype. Int J Gynecol Cancer. 2013; 23:724–729.

25. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999; 59:4525–4528.

26. Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol. 1998; 25:3 Suppl 7. 35–38.

27. Demetri GD, Kris M, Wade J, Degos L, Cella D. Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998; 16:3412–3425.

28. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366:610–618.

29. Sundfor K, Lyng H, Kongsgard UL, Trope C, Rofstad EK. Polarographic measurement of pO2 in cervix carcinoma. Gynecol Oncol. 1997; 64:230–236.

30. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer: meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009; (3):CD007303.